Rearrangement of the MLL gene located at 11q23 is found with over 70 different partner genes in about 5% to 10% of acute leukemia cases. While the most common is the MLL-AF4 fusion resulting from the translocation t(4;11)(q21;q23), several rare and novel partner genes have been detected and characterized throughout the last decade. 1 A novel MLL-ACTN4 was first reported by our group in a case of CD10-B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). 2 The ACTN4 gene located at chromosome 19q13.2 encodes an ubiquitously expressed actin-bundling protein associated with cell motility and cancer invasion. 3 Its mutation or deficiency is mainly associated with focal segmental glomerulosclerosis (FSGS) 4 ; however, its association with leukemogenesis is not clear.
To focus on the identification of MLL-ACTN4 as a rare but recurrent MLL rearrangement, we present two cases of MLL-ACTN4 rearrangement, and compare these patients with regard to diagnostic findings and clinical courses. To our knowledge, these are the only reported cases of MLL-ACTN4 rearrangement so far, and thus a comprehensive analyses of these two MLL-ACTN4 cases possibly provides an insight into this rare MLL rearrangement.
All analyses were done using bone marrow specimens obtained at the time of diagnosis. Based on our findings MLL-ACTN4 rearrangements appear to be therapy-related. Use of topoisomerase-II inhibitors such as mitoxantrone and etoposide is likely to be responsible for therapy related hematologic malignancies with MLL rearrangements, especially involving chromosome bands 11q23 or 21q22. 5 Clinical and laboratory data from both cases suggests the likelihood of cytotoxic (radio-)chemotherapy being responsible for the occurrence of these leukemias. The ACTN4 gene is composed of 21 exons and has a coding capacity of 911 amino acids (Fig. 1) . In both patients, interestingly, the breakpoints were localized in ACTN4 intron 1 which leads to an in-frame fusion of nearly the entire ACTN4 open reading frame (except the first 54 amino acids encoded by exon 1) to the N-terminal portion of MLL gene (Fig. 1 rearrangements are rarely found, little is known of its response to therapy and prognosis.
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